Cerebrolysin vs N-Acetyl Semax
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cerebrolysin
Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.
Full profileN-Acetyl Semax
N-Acetyl Semax is the acetylated form of Semax — an N-terminal acetyl group added to the standard Semax heptapeptide. The modification significantly improves resistance to aminopeptidases, extending the active half-life and producing a more sustained cognitive effect at lower doses. Considered by many researchers to be the preferred form of Semax for neurotrophin upregulation and focus enhancement.
Full profile| Cerebrolysin | N-Acetyl Semax | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture | NA-Semax, Acetyl-Semax, N-Ac-MEHFPGP |
| Evidence | Research-stage | Research-stage |
| Dosing range | 5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access | 100mcg–600mcg mcg, Once daily (intranasal preferred) |
| Administration | Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common) | Intranasal (preferred), Subcutaneous injection |
| Key side effects | Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea | Mild anxiety or over-stimulation at high doses, Nasal irritation (intranasal), Difficulty sleeping if dosed late in the day (more stimulating than standard Semax), Mild appetite suppression |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); N-Acetyl Semax — Intranasal (preferred), Subcutaneous injection.
- Dosing units differ: Cerebrolysin is dosed in mL, N-Acetyl Semax in mcg — they operate at different scales.
- Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; N-Acetyl Semax is Once daily (intranasal preferred).
- Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for N-Acetyl Semax.
How each works
Cerebrolysin
Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.
N-Acetyl Semax
Acetylation of the N-terminus blocks aminopeptidase cleavage at the most vulnerable site on the Semax molecule, extending its effective duration in biological fluids. Studies comparing acetylated vs non-acetylated ACTH fragment analogs consistently show greater stability and sustained receptor engagement with acetylated forms. N-Acetyl Semax demonstrates the same core BDNF/NGF upregulating and neuroprotective profile as Semax with reported greater potency per mcg due to improved bioavailability.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.